S 47445

Drug Profile

S 47445

Alternative Names: CX-1632; S47445

Latest Information Update: 29 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer RespireRx Pharmaceuticals; Servier
  • Class Antidementias; Small molecules
  • Mechanism of Action AMPA receptor agonists; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Major depressive disorder
  • Phase I Dementia; Mild cognitive impairment

Most Recent Events

  • 29 Apr 2016 Phase-II clinical trials in Major depressive disorder (Adjunctive treatment, Treatment-experienced) in Bulgaria and Slovakia (PO) (EudraCT2015-003867-13)
  • 15 Feb 2016 Phase-II clinical trials in Major depressive disorder (Adjunctive treatment, Treatment-experienced) in Finland, Hungary (PO) (EudraCT2015-003867-13)
  • 17 Dec 2015 Cortex Pharmaceuticals is now called RespireRx Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top